ArticleNeuropharmacology2010
Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.
Article in Neuropharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Neurotensin modulation of immune and oxido-inflammatory homeostasis targeting TGF-β activated kinase 1/Nuclear factor-kappa βeta pathway: an integrated in vivo and in silico study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Inactivation of calcium Ion signaling in neuronal SK-N-SH cells with development of resistance to a designer drug α-pyrrolidinooctanophenone.Forensic toxicology · 2026Article
- Differential Effects of Neurotensin NTS1 and NTS2 Receptors on Locomotion.Brain and behavior · 2025Article
- Neurotensin and Neurotensin Receptors in Stress-related Disorders: Pathophysiology & Novel Drug Targets.Current neuropharmacology · 2024Review
- Neuropeptides Modulate Feeding via the Dopamine Reward Pathway.Neurochemical research · 2023Review
- Developmental or adult-onset deletion of neurotensin receptor-1 from dopamine neurons differentially reduces body weight.Frontiers in neuroscience · 2022Article
- Visualization of real-time receptor endocytosis in dopamine neurons enabled by NTSR1-Venus knock-in mice.Frontiers in cellular neuroscience · 2022Article
- Neurotensin receptor 1 deletion decreases methamphetamine self-administration and the associated reduction in dopamine cell firing.Addiction biology · 2021Article
- Association of Neurotensin Receptor 1 Gene Polymorphisms With Defense Mechanisms in Healthy Chinese.Frontiers in psychiatry · 2021Article
- Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Antipsychotic-like effects of a neurotensin receptor type 1 agonist.Behavioural brain research · 2016Article
- Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.Synapse (New York, N.Y.) · 2015Article
- Striatal dopamine receptor plasticity in neurotensin deficient mice.Behavioural brain research · 2015Article
- Activation of neurotensin receptor type 1 attenuates locomotor activity.Neuropharmacology · 2014Article
- Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.Psychopharmacology · 2014Article
- Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.Behavioral sciences (Basel, Switzerland) · 2014Review
- Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat.The Journal of pharmacology and experimental therapeutics · 2013Article
- Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.Journal of molecular neuroscience : MN · 2013Article
- Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity.Molecular metabolism · 2013Article
- Diverse roles of neurotensin agonists in the central nervous system.Frontiers in endocrinology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Neurotensin (NT) is a tridecapeptide that acts as a neuromodulator in the central nervous system mainly through two NT receptors, NTS1 and NTS2. The functional-anatomical interactions between NT, the mesotelencephalic dopamine system, and structures targeted by dopaminergic projections have been studied. The present study was conducted to determine the effects of NT receptor subtypes on dopaminergic function with the use of mice lacking either NTS1 (NTS1(-/-)) or NTS2 (NTS2(-/-)). Basal and amphetamine-stimulated locomotor activity was determined. In vivo microdialysis in freely moving mice, coupled with HPLC-ECD, was used to detect basal and d-amphetamine-stimulated striatal extracellular dopamine levels. In vitro radioligand binding and synaptosomal uptake assays for the dopamine transporters were conducted to test for the expression and function of the striatal pre-synaptic dopamine transporter. NTS1(-/-) and NTS2(-/-) mice had higher baseline locomotor activity and higher basal extracellular dopamine levels in striatum. NTS1(-/-) mice showed higher locomotor activity and exaggerated dopamine release in response to d-amphetamine. Both NTS1(-/-) and NTS2(-/-) mice exhibited lower dopamine D(1) receptor mRNA expression in the striatum relative to wild type mice. Dopamine transporter binding and dopamine reuptake in striatum were not altered. Therefore, lack of either NTS1 or NTS2 alters the dopaminergic system. The possibility that the dysregulation of dopamine transmission might stem from a deficiency in glutamate neurotransmission is discussed. The data strengthen the hypothesis that NT receptors are involved in the pathogenesis of schizophrenia and provide a potential model for the biochemical changes of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.